Compare Intel Corp (INTC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Tango Therapeutics Inc. — how do they compare? Intel Corp trades at $95.56 (market cap $543.46B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Intel Corp is far larger — about 144.9× Tango Therapeutics Inc.'s market cap, and Intel Corp pays a 2.24% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Tango Therapeutics Inc. for 0 Days on average.
| INTC | TNGX | |
|---|---|---|
Market Cap | $543.46B | $3.75B |
Volume | 87,420,405 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $140.94 | $32.90 |
52-Week Low | $33.62 | $7.50 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $564.27B | $2.77B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $102.81, up 1.44% with strong recent earnings beats but faces fundamental challenges including negative net income margin of -19.79% and elevated P/E ratio of 904.17. The stock has shown impressive 2026 momentum with three consecutive quarterly EPS beats, while technical indicators show mixed signals with bearish moving averages but bullish oscillators. Recent news highlights Intel's foundry turnaround efforts and 220% stock surge in 2026, though competition remains intense.
Intel presents a turnaround story with significant execution risks. The foundry business shows growth potential with 31% revenue increase, but negative profitability metrics and high valuation ratios suggest caution. Analyst consensus leans neutral with 54% hold ratings, while the $111.72 price target offers modest upside. Key risks include competitive pressures from TSMC and AMD, margin challenges, and the sustainability of recent stock gains.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
